EUPRAXIA PHARMACEUTICALS INC.
EPRX$428M
Small CapNASDAQBiotechnology🇺🇸North America33 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Dec 15, 2026
40wMarket Overview
Stock performance and key metrics
EPRX News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EP-104IAR 25 mg | Phase 2 | Osteoarthritis, Knee | - | - |
EP-104GI | Phase 2 | Eosinophilic Esophagitis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply